Melinta Therapeutics Demonstrate Delafloxacin's Potent and Rapid Antimicrobial Activity against Neisseria Gonorrhoeae
September 08, 2014 11:01 ET
|
Melinta Therapeutics
NEW HAVEN, Conn, Sept. 8, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today
announced results from in vitro studies that highlight the
potential of delafloxacin, an
investigational fluoroquinolone,...
Melinta Therapeutics and Hartford Hospital Demonstrate Delafloxacin's Potent In-Vitro Activity against Complicated Urinary Tract Infection Pathogens
September 06, 2014 12:01 ET
|
Melinta Therapeutics
NEW HAVEN, Conn, Sept. 6, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics and
Hartford Hospital today announced in vitro results from an
investigator-sponsored study that highlight delafloxacin's...
Melinta Therapeutics Reports on PK Profile of a Single Oral Dose of Delafloxacin in Support of U.S. Phase 3 Gonorrhea Program
September 06, 2014 12:01 ET
|
Melinta Therapeutics
NEW HAVEN, Conn, Sept. 6, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today
announced results of a Phase 1 study of delafloxacin, an
investigational fluoroquinolone, in healthy adults that...
Melinta Therapeutics Highlighting Delafloxacin and ESKAPE Candidates in Twelve Presentations at 2014 ICAAC Meeting
September 04, 2014 10:45 ET
|
Melinta Therapeutics
NEW HAVEN, Conn, Sept. 4, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today
announced that an additional three abstracts have been accepted as
late-breakers at the annual Interscience Conference...
Melinta Therapeutics Reports Top-Line Results Showing Equivalent Exposures after Oral and Intravenous Delafloxacin Administration
August 11, 2014 12:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn, Aug. 11, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today
announced top-line results of a Phase 1 clinical study that
demonstrated that the administration of single doses of...
Melinta Therapeutics Announces Accepted Abstracts at the 2014 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
July 24, 2014 08:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn, July 24, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today
announced that the company and investigators will be making eight
presentations at the annual Interscience Conference...
Melinta Therapeutics to Present at Annual JMP Securities Healthcare Conference
June 17, 2014 14:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn, June 17, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today
announced that CEO Mary Szela will be presenting at the annual JMP
Securities Healthcare Conference in New York, NY....
Melinta Therapeutics Raises $70 Million to Support Delafloxacin NDA and Selection of Multi-Drug Resistant Gram-Negative Candidates from RX-04 Platform
February 10, 2014 07:30 ET
|
Melinta Therapeutics
NEW HAVEN, Conn, Feb. 10, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today
announced the closing of a $70 Million Series 3 equity
financing. Current investor, Vatera Healthcare Partners,...
Melinta Therapeutics Initiates Phase 3 Registration Study of Delafloxacin in Individuals with Uncomplicated Gonorrhea
January 09, 2014 08:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn, Jan. 9, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics
today announced the initiation of a Phase 3 trial of delafloxacin,
a novel investigational fluoroquinolone, for the...
Melinta Therapeutics to Present at J.P. Morgan Healthcare Conference
January 09, 2014 08:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn, Jan. 9, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics
today announced that Mary Szela, the Company's chief executive
officer, will be providing a corporate and clinical update...